DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Diridavumab
Diridavumab
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
ヤンセンファ࣮ч株式会社
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
The Two Tontti Tudiul Lui Hi Ha Unit
(12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
Stembook 2018.Pdf
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
(INN) for Biological and Biotechnological Substances
Challenges with Monoclonal Antibody Therapies for COVID-19
Passive Immunotherapy of Viral Infections: 'Super-Antibodies'
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
International Nonproprietary Names for Pharmaceutical Substances (INN)
Understanding Drug Resistance and Antibody Neutralization Escape in Antivirals: a Dissertation
INN-Nimet 1 27.11.2018 a Abacavir Abacavirum Abakaviiri Abagovomab
Challenges and Opportunities for Antiviral Monoclonal Antibodies As COVID-19 Therapy
Gm, Ke, Lr, Ls, Mw, Mz, Na, Rw, Sd, Sl, St, Sz, Tz, Ug, Zm, Zw
Top View
QSAR Model Development for Early Stage Screening of Monoclonal Antibody Therapeutics to Facilitate Rapid Developability
(INN) for Biological and Biotechnological Substances
Computational Methods to Develop Potential Neutralizing Antibody Fab Region Against SARS-Cov-2 As Therapeutic and Diagnostic Tool Hemanth K
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri